Fabrice Egros - Nov 18, 2021 Form 4 Insider Report for Syndax Pharmaceuticals Inc (SNDX)

Role
Director
Signature
/s/ Michael A. Metzger, Attorney-in-Fact
Stock symbol
SNDX
Transactions as of
Nov 18, 2021
Transactions value $
-$127,737
Form type
4
Date filed
11/19/2021, 03:06 PM
Previous filing
Aug 20, 2021
Next filing
Feb 3, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SNDX Common Stock Options Exercise $125K +14K +87.5% $8.93 30K Nov 18, 2021 Direct
transaction SNDX Common Stock Sale -$252K -14K -46.67% $18.03 16K Nov 18, 2021 Direct F1, F2
transaction SNDX Common Stock Options Exercise $236 +30 +0.19% $7.88 16K Nov 18, 2021 Direct
transaction SNDX Common Stock Sale -$541 -30 -0.19% $18.03 16K Nov 18, 2021 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SNDX Stock Options (Right to buy) Options Exercise $0 -14K -100% $0.00* 0 Nov 18, 2021 Common Stock 0 $8.93 Direct F3
transaction SNDX Stock Options (Right to buy) Options Exercise $0 -30 -100% $0.00* 0 Nov 18, 2021 Common Stock 0 $7.88 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person.
F2 The sale prices ranged from $18.03 to $19.03.
F3 This option is fully vested.